Shopping Cart
- Remove All
Your shopping cart is currently empty
Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate comprising a Thalidomide-based cereblon ligand and a linker.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $40 | In Stock | |
| 10 mg | $57 | In Stock | |
| 25 mg | $93 | In Stock | |
| 50 mg | $137 | In Stock | |
| 100 mg | $247 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $71 | In Stock |
| Description | Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate comprising a Thalidomide-based cereblon ligand and a linker. |
| In vitro | PROTACs consist of two ligands connected by a linker, one targeting an E3 ubiquitin ligase and the other targeting the protein of interest. They leverage the intracellular ubiquitin-proteasome system to selectively degrade target proteins [1]. |
| Synonyms | E3 Ligase Ligand-Linker Conjugates 25 Trifluoroacetate, E3 Ligase Ligand-Linker Conjugates 25 TFA, Cereblon Ligand-Linker Conjugates 11 TFA |
| Molecular Weight | 1087.95 |
| Formula | C46H53F6N8O16 |
| Cas No. | 1950635-14-9 |
| Smiles | O=C(NCCCCCCN)COC1=CC=CC(C(N2C(CC3)C(NC3=O)=O)=O)=C1C2=O.O=C(O)C(F)(F)FC1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)OCC(=O)NCCCCCCN.C(=O)(C(F)(F)F)O |
| Relative Density. | 1.31g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 105.5 mg/mL (96.97 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (4.6 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.